@article{fc07b6bcfef546a99c5ad97940733230,
title = "Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer",
abstract = "To evaluate the effect of bicalutamide ('Casodex') 150mg (in addition to standard care), on the risk of prostate-specific antigen (PSA) progression, in patients with early prostate cancer.",
keywords = "Adult, Aged, Aged, 80 and over, Androgen Antagonists, Anilides, Chemotherapy, Adjuvant, Disease Progression, Double-Blind Method, Humans, Male, Middle Aged, Neoplasm Staging, Nitriles, Proportional Hazards Models, Prostate-Specific Antigen, Prostatectomy, Prostatic Neoplasms, Risk Factors, Survival Analysis, Tosyl Compounds",
author = "W See and P Iversen and M Wirth and D McLeod and L Garside and T Morris",
year = "2003",
language = "English",
volume = "44",
pages = "512--7; discussion 517--8",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier BV",
number = "5",
}